Group
anti-HER2 mAb
The data below refer to patients treated with anti-HER2 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Trastuzumab
Margetuximab
No data
Pertuzumab
No data
Pertuzumab + hyaluronidase
No data
Pertuzumab + trastuzumab + hyaluronidase
No data
Zanidatamab
No data
Zenocutuzumab
No data